41
st Annual Meeting of September 5-6, 2020 the Endocrine Society and the Diabetes Association of the R.O.C. (Taiwan)
The
OD-1
CARDIOVASCULAR EFFECTIVENESS AND SAFETY OF EMPAGLIFLOZIN IN ROUTINE CARE IN EAST ASIA: RESULTS FROM THE EMPRISE STUDY 1
WAYNE H-H SHEU, 2ELISE CHIA-HUI TAN, 3YUTAKA SEINO, 4DAE JUNG KIM, 5 DAISUKE YABE, 4KYOUNG HWA HA, 6WEI-YU LEI, 7WOOK-JIN CHUNG, 8 ATSUTAKA YASUI, 9RIHO KLEMENT, 10MOE KYAW, 10KIMBERLY G. BRODOVICZ 1
Division of Endocrinology and Metabolism, Taichung Veterans General Hospital, Taichung, Taiwan; National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan, and Institute of Hospital and Health Care Administration, National Yang-Ming University, Taipei, Taiwan; 3Kansai Electric Power Medical Research Institute, Kobe, Japan; 4Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea; 5Kansai Electric Power Medical Research Institute, Kobe, Japan, and Department of Diabetes and Endocrinology, Gifu University Graduate School of Medicine, Gifu, Japan; 6Boehringer Ingelheim Taiwan Ltd., Taipei, Taiwan; 7Department of Cardiovascular Medicine, Gachon University Gil Medical Center, Incheon, Korea; 8Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan; 9EPID Research, Tartu, Estonia; 10Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA 2
Background: Empagliflozin reduced the risks of cardiovascular (CV) death and hospitalization for heart failure (HHF) in type 2 diabetes mellitus (T2DM) patients and established CV disease in the EMPA-REG OUTCOME trial. The Empagliflozin Comparative Effectiveness and Safety Study (EMPRISE) is comparing the effectiveness, safety, and healthcare utilization of empagliflozin versus dipeptidyl peptidase-4 inhibitors (DPP-4i) in routine clinical care across the CV risk continuum in Asia, Europe, and the US. Analyses of EMPRISE in the US showed that empagliflozin was associated with a lower risk of CV outcomes. Methods: We analyzed data from three East Asian countries in EMPRISE (Japan, South Korea, and Taiwan) for T2DM patients aged ≥ 18 years before initiated empagliflozin or a DPP-4i. Exclusion criteria included prescription of any SGLT2i/DPP-4i in the prior 12 months, diagnosis of type 1 diabetes mellitus/gestational diabetes at any time, or diagnosis of end-stage renal disease (ESRD) in the prior 12 months. Sub-cohorts of empagliflozin and DPP-4i initiators were identified by propensity score matching (1:1) with > 120 covariates. The meta-analyses were conducted for the primary effectiveness outcomes (HHF, ESRD and all-cause mortality [ACM]). Results: In total, 892,355 patients initiated either empagliflozin or a DPP-4i (Japan 343,329; South Korea 263,524; Taiwan 285,502), with 28,712 matched pairs of patients (Japan 5,592 pairs; South Korea 9,072 pairs; Taiwan 14,048 pairs). Empagliflozin was associated with significant 21% (p-value = 0.023), 36% (p-value < 0.001) and 63% (p-value < 0.001) reductions in the risk of HHFspecific, ACM and ESRD, respectively. Conclusions: The results provide insight into the effectiveness of empagliflozin in routine care of T2DM in East Asia. 112
